Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

In the third quarter, Eli Lilly's sales grew by 20% year over year to $11.4 billion, largely thanks to Zepbound and Mounjaro.

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) shares gapped up before the market opened on Friday .The stock had previously closed at $757.54, but opened at $811.35. Eli Lilly and Company ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...